Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 2Surgical Wound Infection 1Sepsis 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Glioblastoma 1Febrile Neutropenia 1Exanthema 1Discitis 1Diarrhea 1Colonic Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × Anti-Bacterial Agents × Clear all
NCT01967758 2018-08-17

Phase I Study of Safety and Immunogenicity of ADU-623

Providence Health & Services

Phase 1 Completed
11 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡